| Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. | |
| | |
MedLine Citation:
|
PMID: 22229414 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Approximately 20-30% of breast cancers show increased expression of the HER2 receptor tyrosine kinase. Trastuzumab (Herceptin) is a clinically approved anti-HER2 monoclonal antibody. Many patients with HER2-overexpressing metastatic breast cancer respond to trastuzumab; however, a subset display primary drug resistance. In addition, many patients who initially respond to trastuzumab ultimately develop disease progression. Multiple molecular mechanisms contributing to trastuzumab resistance have been proposed in the literature. These mechanisms include cross-signaling from related HER/erbB receptors and compensatory signaling from receptors outside of the HER/erbB family, including receptors for insulin-like growth factor-I, vascular endothelial growth factor, and transforming growth factor beta. The major downstream signaling pathway activated by HER2 cross-talk is PI3K/mTOR, and a potential integrator of receptor cross-talk is Src-focal adhesion kinase (FAK) signaling. PI3K, Src, and FAK have independently been implicated in trastuzumab resistance. In this review, we will discuss pharmacological inhibition of HER2 cross-talk as a strategy to treat trastuzumab-refractory HER2-overexpresssing breast cancer. |
| | |
Authors:
|
R Nahta |
Related Documents
:
|
12486804 - Role of serotonin, gamma-aminobutyric acid, and glutamate in the behavioral thermoregul... 14686914 - Glutamate signaling in peripheral tissues. 2832594 - Excitatory amino acid receptor-mediated transmission of somatosensory evoked potentials... 22963434 - Regulation of p2x3 receptor structure and function. 9449704 - Inducible inactivation of hepatic lrp gene by cre-mediated recombination confirms role ... 12716944 - Functional nmda receptor subtype 2b is expressed in astrocytes after ischemia in vivo a... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Current medicinal chemistry Volume: 19 ISSN: 1875-533X ISO Abbreviation: Curr. Med. Chem. Publication Date: 2012 |
Date Detail:
|
Created Date: 2012-03-05 Completed Date: 2012-07-19 Revised Date: 2013-05-08 |
Medline Journal Info:
|
Nlm Unique ID: 9440157 Medline TA: Curr Med Chem Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1065-75 Citation Subset: IM |
Affiliation:
|
Departments of Pharmacology, Emory University School of Medicine, USA. rnahta@emory.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal, Humanized
/
therapeutic use* Antineoplastic Agents / therapeutic use Breast Neoplasms / drug therapy* Chemistry, Pharmaceutical Dimerization Drug Design* Drug Resistance, Neoplasm / drug effects* Female Humans Receptor Cross-Talk / drug effects* Receptor, erbB-2 / metabolism* Receptor, erbB-3 / metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
3K01CA118174-5S1/CA/NCI NIH HHS; K01 CA118174/CA/NCI NIH HHS; K01 CA118174-05/CA/NCI NIH HHS; K01 CA118174-05S1/CA/NCI NIH HHS; K01 CA118174-06/CA/NCI NIH HHS; K01CA118174/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; EC 2.7.10.1/Receptor, erbB-2; EC 2.7.10.1/Receptor, erbB-3; P188ANX8CK/trastuzumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The kinase activity of the Helicobacter pylori Asp-tRNA(Asn)/Glu-tRNA(Gln) amidotransferase is sensi...
Next Document: Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis.